01 - Our Mission
Breakthrough medecine by personalization.
The goal of The University Hospital Federation APOLLO is to provide a personalized therapeutic response to the main causes of human mortality in the world, namely cardiovascular, pulmonary and chronic renal diseases, as well as to the phenomenon of rejection in solid organ transplants.
Every day we increase human knowledge of the processes of fibrosis, inflammation and remodeling, which are the three main origins of these diseases.
May 13, 2022
Deployment and development of the Precision Pathology Platform of the Paris Transplant Group
The Paris Transplant Group (PTG) Precision Pathology Platform specializes in RNA/DNA extraction from all types of samples (FFPE, frozen tissues, plasma, etc….) and its analysis (transcriptomic or genomic) using various tools such as the NanoString® nCounter™ or, more recently, the CareDx® AlloSeq™ assay detecting the presence of circulating donor-derived DNA (dd-cfDNA).
02 - Our Approach
APOLLO, an engine of discovery.
By 2030, cardiovascular disease and chronic lung disease will be the two leading causes of death worldwide and, together with chronic kidney disease, they represent a major threat to the global human health care system.
These diseases share important pathophysiological processes, as they all involve fibrosis, inflammation and chronic remodeling that progressively alter the structure of native or transplanted organs, impairing their function, leading to acute and then chronic failure and ultimately death.
Therefore, scientific findings on fibrosis, inflammation and remodeling are major targets for new preventive and curative therapeutic strategies.
02 - Our Approach
Our Research Strategy
02 - Our Approach
APOLLO proposes an integrative assessment combining standard of care, molecular medicine, functional imaging and health information technologies to provide a precision monitoring and diagnostic system applied to patients with chronic cardiovascular, respiratory and renal diseases and to solid organ transplant patients.
With a consortium of 26 clinical partners (APHP), 18 research partners (INSERM, University of Paris) and pharmaceutical companies, APOLLO has a broad reach and will make major contributions to all levels of outcomes in chronic cardiovascular, respiratory, renal and organ transplantation diseases.
APOLLO will not only have a direct impact on patient care, but also has the ambition to transform the entire value chain of chronic disease management; improving the future of research, the future of care delivery, the future of precision medicine, the future of patients and medical education.
03 - Our Missions
The 5 missions of APOLLO
Mission WP1, Fight Fibrosis.
1 - Dissect the link between inflammation and fibrosis.
2 - Decipher the genetic basis of extracellular matrix remodeling and fibrosis.
3 - Identify biomarkers and develop clinical trials in the field of tissue remodeling and fibrosis.
Mission WP2, Multi-physics imaging for diagnosis.
1 - Multi-physics imaging for early detection and staging of fibrosis and inflammation.
2 - Integration of multi-physics imaging with molecular and conventional diagnostics.
Mission WP3, Assessment of immune and non-immune factors in the overall atherosclerotic disease process.
1 - Develop innovative epidemiological approaches that can have a greater impact in cardiovascular and renal prevention.
2 - Demonstrate that circulating PCSK9 concentrations can predict the occurrence of cardiovascular events in high-risk populations.
3 - To study the long-term impact of treatment of chronic inflammatory oral infections on atherosclerotic plaque activity in myocardial infarction survivors.
4 - To establish the prevalence of sleep-disordered breathing in clinical populations with an acute cardiovascular event.
Mission WP4, From inflammation to fibrosis in solid organ transplants.
1 - Building the largest multi-organ transplant cohort in Europe with prospective and standardized data and collection of blood and tissue samples: The Paris-North transplant cohort.
2 - Elucidate the molecular architecture of chronic inflammation in the heart, lung and kidney based on gene expression analysis of grafts and understand the underlying mechanisms of inflammation-induced fibrogenesis.
3 - Provide precision diagnostic algorithms by generating equations derived from biomarkers and gene sets/classifiers that accurately classify the cause, activity and stage of disease in inflammation and fibrosis in solid organ transplants.
Mission WP5, APOLLO Digital Hub: from research to patients.
1 - Building APOLLO-hom-ics: The data infrastructure will integrate the APOLLO cohorts provided by WP1, WP2, WP3 and WP4 and the data generated by the APOLLO platforms.
2 - Digital platform to inform and prepare patients for hospitalization and to connect hospital and ambulatory.
3 - Evaluation of use cases and transformations of self-representation from the patient and caregiver perspective will address adherence, compliance and acceptability of connected care, as part of the Person in Medicine program.
APOLLO Research Strategy
04 - Our Science
APOLLO project has a broad scope and will make major contributions at all levels of cardiovascular, respiratory, renal chronic disease and organ transplant outcomes.
This will not only impact directly on the patients’ care, but has the ambition to transform the entire value chain in chronic disease management.
April 05, 2022
Risk stratification and screening for coronary artery disease in asymptomatic patients with diabetes mellitus: Position paper of the French Society of Cardiology and the French-speaking Society of Diabetology
Coronary risk stratification should be considered as a critical step to decide whether or not to perform CAD screening, and to define therapeutic goals and optimal treatments.
November 16, 2021
The emerging field of non–human leukocyte antigen antibodies in transplant medicine and beyond
In this review, we will provide a comprehensive summary of the paradigm-changing concept of immunity to the non-HLA angiotensin II type 1 receptor (AT1R), discovered by Duška Dragun et al., that began from careful bedside clinical observations, to validated detection of anti-AT1R antibodies and lead to clinical intervention.
April 05, 2022
Bariatric surgery induces a new gastric mucosa phenotype with increased functional glucagon-like peptide-1 expressing cells
In summary, this report brings to light the presence of gastric GLP-1-positive cells whose density in the mucosa increases after RYGB and VSG surgeries. It highlights a potential role of stomach-derived GLP-1 acting locally and ascribes a role in physiology and metabolism.